375 related articles for article (PubMed ID: 32141247)
1. Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients.
Bae MH; Cho Y; Hwang J; Park HS; Han S; Lee YS; Cho HJ; Jung BC; Lee CH; Hyun DW; Park JS; Ahn J; Kim KH; Shin DG
J Korean Med Sci; 2020 Mar; 35(9):e49. PubMed ID: 32141247
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
[TBL] [Abstract][Full Text] [Related]
3. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
[TBL] [Abstract][Full Text] [Related]
5. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
[TBL] [Abstract][Full Text] [Related]
6. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
7. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.
Clementy N; Challal F; Marijon E; Boveda S; Defaye P; Leclercq C; Deharo JC; Sadoul N; Klug D; Piot O; Gras D; Bordachar P; Algalarrondo V; Fauchier L; Babuty D;
Heart Rhythm; 2017 Feb; 14(2):211-217. PubMed ID: 27989789
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
[TBL] [Abstract][Full Text] [Related]
11. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score.
van Rees JB; Borleffs CJ; van Welsenes GH; van der Velde ET; Bax JJ; van Erven L; Putter H; van der Bom JG; Schalij MJ
Heart; 2012 Jun; 98(11):872-7. PubMed ID: 22581736
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
[TBL] [Abstract][Full Text] [Related]
13. Benefit of Implantable Cardioverter-Defibrillator Generator Replacement in a Primary Prevention Population-Based Cohort.
Weng W; Sapp J; Doucette S; MacIntyre C; Gray C; Gardner M; Abdelwahab A; Parkash R
JACC Clin Electrophysiol; 2017 Oct; 3(10):1180-1189. PubMed ID: 29759503
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients.
Lee JH; Yu HT; Oh IY; Choi EK; Sung JH; Lee YS; Kim JY; Baek Y; Park J; Joung B;
Yonsei Med J; 2020 Nov; 61(11):942-950. PubMed ID: 33107237
[TBL] [Abstract][Full Text] [Related]
18. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
[TBL] [Abstract][Full Text] [Related]
20. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.
Dichtl W; Wolber T; Paoli U; Brüllmann S; Stühlinger M; Berger T; Spuller K; Strasak A; Pachinger O; Haegeli LM; Duru F; Hintringer F
Clin Cardiol; 2011 Jul; 34(7):433-6. PubMed ID: 21678454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
